Ecnoglutide

Overview

What is Ecnoglutide and what does the research say?

Identity

Also Known As

XW003 • Sciwind GLP-1

How It Works (Simplified)

Ecnoglutide (XW003) is a long-acting GLP-1 receptor agonist designed for once-weekly subcutaneous injection. It mimics the incretin hormone GLP-1 to suppress appetite, slow gastric emptying, and enhance glucose-dependent insulin secretion. Developed by Sciwind Biosciences, it represents China’s entry into the competitive GLP-1 obesity therapeutics market.

Scientific Pathways

GLP-1 Receptor Activation: Like other GLP-1 receptor agonists, ecnoglutide binds to and activates GLP-1 receptors in the pancreas, brain, and GI tract. This triggers multiple downstream effects: enhanced insulin secretion (glucose-dependent), suppressed glucagon release, delayed gastric emptying, and central satiety signaling in the hypothalamus.

Engineering for Duration: Ecnoglutide incorporates structural modifications to resist DPP-4 enzymatic degradation and extend half-life, enabling once-weekly dosing comparable to semaglutide.

Clinical Evidence

Phase 3 Weight Loss Data: Phase 3 trials conducted primarily in Chinese populations demonstrated 14.7% body weight reduction at 26 weeks with ecnoglutide at the therapeutic dose. The efficacy is competitive with first-generation weekly GLP-1 agonists, though direct head-to-head comparisons are not yet available.

Glycemic Control: Phase 3 data also showed significant HbA1c reduction in patients with type 2 diabetes, supporting potential dual indications for obesity and diabetes.

Safety Profile

The safety profile is consistent with the GLP-1 receptor agonist class, with gastrointestinal adverse events (nausea, vomiting, diarrhea) as the most common side effects. No unique safety signals beyond the established GLP-1 class effects have been reported. Safety data is primarily from Chinese patient populations; global generalizability awaits broader trials.

Important Limitations

• Phase 3 data primarily from Chinese populations; global applicability uncertain
• No FDA submission planned in the near term
• Weight loss (14.7% at 26 weeks) lower than leading competitors (semaglutide ~15-17%, tirzepatide ~20-26%)
• No head-to-head trials against established GLP-1 therapies
• Not available outside clinical trials in China
• Limited English-language publication of trial data

Peptide Interactions

Known and theoretical interactions when combining Ecnoglutide with other peptides. Based on published research and mechanistic considerations.

Synergistic

Compatible

Caution

Avoid

Semaglutide

Avoid

Avoid

Both are GLP-1 receptor agonists. Co-administration would provide redundant GLP-1 agonism with increased risk of GI adverse events.

Tirzepatide

Avoid

Avoid

Both target GLP-1 receptors. Combining would create overlapping mechanisms with increased adverse event risk.

Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.

References

10 Sources

6 Human

4 Preclinical

Full reference list available on request. All citations link to PubMed for verification.

Methodology Note

This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.

For complete methodology details, see our Methodology page.